The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma
The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma
ABSTRACT
Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple
myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of
___
- Ljungman P, Bregni M, Brune M, et al. Allogeneic and
autologous transplantation for haematological diseases, solid
tumours and immune disorders: current practice in Europe
2009. Bone Marrow Transplant 2010;45:219-34. doi: 10.1038/
bmt.2009.141
- Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT
activity survey: 1990-2010. Bone Marrow Transplant
2012;47:906-23. doi: 10.1038/bmt.2012.66
- Arora S, Majhail NS, Liu H. Hematopoietic progenitor cell
mobilization for autologous stem cell transplantation in
multiple myeloma in contemporary era. Clin Lymphoma
Myeloma Leuk 2019;19:200-5. doi: 10.1016/j.clml.2018.12.010
- Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic
stem cell mobilisation in multiple myeloma and lymphoma
patients: a position statement from the European Group for
Blood and Marrow Transplantation. Bone Marrow Transplant
2014;49:865-72. doi: 10.1038/bmt.2014.39
- Giralt S, Costa L, Schriber J, et al. Optimizing autologous
stem cell mobilization strategies to improve patient outcomes:
consensus guidelines and recommendations. Biol of Blood
Marrow Transplant 2014;20:295-308. doi: 10.1016/j.
bbmt.2013.10.013
- Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+
cell monitoring after cyclophosphamide and granulocytecolony-
stimulating factor: an algorithm for the pre-emptive
use of plerixafor. Leukemia Lymphoma 2014;55:331-6. doi:
10.3109/10428.194.2013.802783
- Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage
poor mobilizers for high dose chemotherapy and autologous
stem cell transplantation? Transfusion Apher Sci 2017;56:190-
8. doi: 10.1016/j.transci.2016.11.005
- Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of
hematopoietic stem cells-definitions, incidence, risk factors,
and impact on outcome of autologous transplantation. Biol
Blood Marrow Transplant 2010;16:490-9. doi: 10.1016/j.
bbmt.2009.11.012
- Lee JL, Kim SB, Lee GW, et al. Collection of peripheral blood
progenitor cells: analysis of factors predicting the yields.
Transfus Apher Sci 2003;29:29-37. doi: 10.1016/s1473-
0502(03)00097-1
- Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell
mobilization following induction therapy with lenalidomide
in myeloma. Leukemia 2008;22:1282-4. doi: 10.1038/
sj.leu.2405100
- Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition
of ‘poor mobilizer’ in lymphoma and multiple myeloma: an
analytic hierarchy process by ad hoc working group Gruppo
ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant
2012;47:342-51. doi: 10.1038/bmt.2011.82
- Shah EE, Young RP, Wong SW, et al. Impact of plerixafor use at
different peripheral blood cd34(+) thresholds on autologous
stem cell collection in patients with multiple myeloma.
Blood Marrow Transplant 2020;26:876-83. doi: 10.1016/j.
bbmt.2019.11.024
- Douglas KW, Gilleece M, Hayden P, et al. UK consensus
statement on the use of plerixafor to facilitate autologous
peripheral blood stem cell collection to support high-dose
chemoradiotherapy for patients with malignancy. J Clin Apher
2018;33:46-59. doi: 10.1002/jca.21563
- Keating GM. Plerixafor: a review of its use in stem-cell
mobilization in patients with lymphoma or multiple myeloma.
Drugs 2011;71:1623-47. doi: 10.2165/11206.040.000000000-
00000
- Cooper DL, Medoff E, Patel N, et al. Autologous stem
cell mobilization in the age of plerixafor. Clin Lymphoma
Myeloma Leuk 2016;16:411-6. doi: 10.1016/j.clml.2016.04.007
- Spoerl S, Peter R, Wäscher D, et al. Patients’ outcome
after rescue plerixafor administration for autologous stem
cell mobilization: a single-center retrospective analysis.
Transfusion 2017;57:115-21. doi: 10.1111/trf.13883
- Gambell P, Herbert K, Dickinson M, et al. Peripheral blood
CD34+ cell enumeration as a predictor of apheresis yield:an analysis of more than 1,000 collections. Blood Marrow
Transplant 2012;18:763-72. doi: 10.1016/j.bbmt.2011.10.002
- Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA.
Identification of the CD34 enumeration on the day before stem
cell harvest that best predicts poor mobilization. Transfusion
2011;51:587-90. doi: 10.1111/j.1537-2995.2010.02891.x
- Sancho JM, Morgades M, Grifols JR, et al. Predictive factors
for poor peripheral blood stem cell mobilization and peak
CD34(+) cell count to guide pre-emptive or immediate
rescue mobilization. Cytotherapy 2012;14:823-9. doi:
10.3109/14653.249.2012.681042
- Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV,
Stuart RK. Development and validation of a decision-making
algorithm to guide the use of plerixafor for autologous
hematopoietic stem cell mobilization. Bone Marrow
Transplant 2011;46:64-9. doi: 10.1038/bmt.2010.78
- Solá C, Maroto P, Salazar R, et al. Bone marrow transplantation:
prognostic factors of peripheral blood stem cell mobilization
with cyclophosphamide and filgrastim (r-metHuG-CSF): The
CD34+ cell dose positively affects the time to hematopoietic
recovery and supportive requirements after high-dose
chemotherapy. Hematology (Amsterdam, Netherlands)
1999;4:195-209. doi: 10.1080/10245.332.1999.11746443
- Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive
strategy results in high success rates in autologous stem
cell mobilization failure. J Clin Apher 2017;32:224-34. doi:
10.1002/jca.21496
- Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness
analysis of a risk-adapted algorithm of plerixafor use
for autologous peripheral blood stem cell mobilization.
Blood Marrow Transplant 2013;19:87-93. doi: 10.1016/j.
bbmt.2012.08.010
- Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and costbenefit
analysis of risk-adaptive use of plerixafor for autologous
hematopoietic progenitor cell mobilization. Transfusion
2012;52:55-62. doi: 10.1111/j.1537-2995.2011.03206.x